Lawrence H. Einhorn, M.D., has been widely recognized for his success in medical oncology and in the development of a curative treatment for testis cancer, the most common cancer in young men.

Dr. Einhorn pursued his undergraduate education at Indiana University Bloomington. He received his medical education at the University of Iowa, but returned to Indiana University for a residency in internal medicine and a portion of his fellowship in hematology/oncology. He joined the Indiana University faculty in 1973 and was named a distinguished professor of medicine in 1987.

Dr. Einhorn’s most recognized accomplishment is his development in 1974 of a chemotherapy regimen for disseminated testis cancer that revolutionized the results of therapy and is responsible for a dramatic improvement in the cure rate of what previously had been a devastating and rapidly fatal disease. Throughout his career, Dr. Einhorn has been a critical observer and a student of this disease and has carefully studied its nuances. Primarily because of his efforts and those of Dr. John P. Donohue, more than 95 percent of all patients with this disease who seek treatment at a major medical center now survive. The current chemotherapy regimen is well-tolerated; after treatment, patients return to their families to live productive, healthy lives.

Testis cancer is not Dr. Einhorn’s only area of expertise. He is also an internationally recognized authority on other types of urologic cancer, lung cancer, and certain other tumors, and his publications number in the hundreds. Few medical oncologists have had as profound an impact on cancer treatment.

Dr. Einhorn’s accomplishments are noted by his numerous awards. He has received the most prestigious awards of both the American Association for Cancer Research (Richard and Hinda Rosenthal Award) and of the American Society of Clinical Oncology (Karnofsky Award). He has also received the General Motors Kettering Award for Cancer Research and the American Cancer Society Medal of Honor. Dr. Einhorn was honored on August 19, 2009, with the ringing of the New York Stock Exchange Bell for the ASCO Cancer Foundation. He became President of the American Society of Clinical Oncology (ASCO) from 2000-2001. He was elected to membership in the National Academy of Sciences and American Philosophical Society in 2002.

Dr. Einhorn is highly respected by medical students and house staff as a lecturer, clinician, and bedside teacher. His dedication to the training program in hematology/oncology has stimulated nearly 50 percent of all trainees in the program to enter academic medicine. Many of these individuals have become nationally respected authorities in the field of cancer in their own right.